EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis

Caiyun Liu, Lin Meng, Lixin Wang, Bin Dong, Like Qu, Chuanke Zhao, Chengchao Shou

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2025.101299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Caiyun Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry & Molecular Biology, Peking U…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Vascular Endothelial Growth Factor Receptor-2, Drug Resistance, Neoplasm, Neovascularization, Pathologic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Peking University Health Science Center, Natural Science Foundation of Beijing Municipality, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Resistance to Bevacizumab (Bev) remains a major obstacle in colorectal cancer (CRC) treatment. Gamma-synuclein (SNCG), overexpressed in tumor vasculature and cancer cells, is investigated here for its role in Bev resistance and therapeutic potential. METHODS: Using isogenic CRC models with SNCG overexpression or knockout, we assessed SNCG's impact on Bev response in vitro and in vivo. The therapeutic efficacy of combining Bev with an anti-SNCG monoclonal antibody (42#) was evaluated in Bev-resistant models. Mechanistic studies, including ELISA, Western blot, surface plasmon resonance (SPR), and molecular docking, explored interactions between SNCG, VEGF, and VEGFR2. RESULTS: SNCG overexpression reduced Bev sensitivity by impairing the inhibition of migration, invasion, and spheroid formation, whereas SNCG knockout enhanced therapeutic response. Molecular docking revealed that SNCG binds VEGFR2 at an allosteric site, forming a stable ternary complex (SNCG-VEGF-VEGFR2) with enhanced hydrogen bonding, which sustained VEGFR2 phosphorylation and angiogenesis. In vivo, SNCG-overexpressing tumors showed reduced responsiveness to Bev (42.8 % inhibition vs. 64.3 % in controls, p < 0.05), while SNCG-deficient tumors exhibited a 3.2-fold increase in sensitivity. Combining Bev with 42# synergistically suppressed tumor growth (0.70 ± 0.36 g vs. 1.55 ± 0.41 g, p = 0.003), reduced metastatic burden (0.29 ± 0.23 g vs. 0.97 ± 0.42 g, p = 0.006), and extended median survival (86.8 vs. 69.8 days, p = 0.033) in Bev-resistant models. CONCLUSIONS: SNCG drives Bev resistance in CRC by forming a ternary complex with VEGF and VEGFR2, enhancing VEGFR2 signaling and angiogenesis. Dual targeting of VEGF and SNCG represents a promising therapeutic strategy to overcome Bev resistance, with the potential to improve outcomes in CRC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsVascular Endothelial Growth Factor Receptor-2Drug Resistance, NeoplasmNeovascularization, PathologicBevacizumabgamma-SynucleinHumansAnimalsMolecular Docking SimulationMiceXenograft Model Antitumor AssaysCell Line, TumorAngiogenesis InhibitorsVascular Endothelial Growth Factor AMice, NudeCell MovementAngiogenesisNeoplasm Proteins

Stichwörter der Autor:innen

Bevacizumab resistanceVEGFR2angiogenesiscolorectal cancer (CRC)gamma-synuclein (SNCG)

Substanzen

Vascular Endothelial Growth Factor Receptor-2Bevacizumabgamma-SynucleinKDR protein, humanAngiogenesis InhibitorsSNCG protein, humanVascular Endothelial Growth Factor ANeoplasm Proteins

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry & Molecular Biology, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian Dis…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing 100142, China.

Förderung

  • Peking University Health Science Center
  • Natural Science Foundation of Beijing Municipality
  • National Key Research and Development Program of China

Zitieren

APA

Liu, C., Meng, L., Wang, L., Dong, B., Qu, L., Zhao, C., & Shou, C. (2026). Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101299

Vancouver

Liu C, Meng L, Wang L, Dong B, Qu L, Zhao C, et al. Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101299

BibTeX
@article{Liu2026,
  author = {Liu, Caiyun and Meng, Lin and Wang, Lixin and Dong, Bin and Qu, Like and Zhao, Chuanke and Shou, Chengchao},
  title = {Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2025.101299}
}
Kostenlos starten →